Please find enclosed herewith the newspaper publication regarding the publication of Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bliss GVS Pharma Ltd has published its audited financial results for Q4 and the full year ended March 31, 2026. On a standalone basis, total income grew 9.96% to ₹77,352.63 lakh from ₹70,342.11 lakh, while net profit jumped 40.46% to ₹9,687.44 lakh from ₹6,896.87 lakh. On a consolidated basis, total income crossed the ₹1,00,000 lakh mark at ₹1,00,064.26 lakh (up 18.25% from ₹84,621.97 lakh), and net profit rose 49.25% to ₹13,472.77 lakh from ₹9,025.53 lakh. Basic EPS for standalone FY26 stood at ₹9.17 versus ₹6.56 in the prior year, and at ₹12.23 on a consolidated basis versus ₹8.02. The Board has recommended a final dividend of ₹1 per share, subject to shareholder approval at the AGM.
Strong double-digit growth in both standalone and consolidated revenue and profit for FY26 is a positive signal. The jump in consolidated net profit of nearly 50% year-on-year is particularly encouraging for shareholders and could support a positive re-rating of the stock.